Synapse

← Jürgen C. Becker

Papers by Jürgen C. Becker

Page 5 · newest first

  1. Mouse models for melanoma: a personal perspectiveExperimental Dermatology · 2009
  2. Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem CellsCancer Research · 2009
  3. Quantitation of Human Seroresponsiveness to Merkel Cell PolyomavirusPLoS Pathogens · 2009
  4. The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenasePLoS ONE · 2009
  5. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100BClinical Cancer Research · 2009
  6. Surgical regenerative treatment of peri‐implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane: a four‐year clinical follow‐up reportJournal Of Clinical Periodontology · 2009
  7. Identification of heme oxygenase-1–specific regulatory CD8+ T cells in cancer patientsJournal of Clinical Investigation · 2009
  8. Oligoclonal CD4⁺T Cells Promote Host Memory Immune Responses to Zwitterionic Polysaccharide ofStreptococcus pneumoniaeInfection and Immunity · 2009
  9. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassaysInternational Journal of Cancer · 2009
  10. Identification and characterization of survivin‐derived H‐2Kb‐restricted CTL epitopesEuropean Journal of Immunology · 2009
  11. Molecular pathogenesis of Merkel cell carcinomaExperimental Dermatology · 2009
  12. Therapy of metastasized Merkel cell carcinoma with liposomal doxorubicin in combination with radiotherapyJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2009
  13. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent endothelialisation)EuroIntervention · 2009
  14. CD147 Impacts Angiogenesis and Metastasis FormationCancer Investigation · 2009
  15. Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalpBritish Journal of Dermatology · 2008
  16. Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populationsJournal of Translational Medicine · 2008
  17. Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2DThe Journal of Immunology · 2008
  18. CD7 − T Cells are Late Memory Cells Generated from CD7 + T CellsRejuvenation Research · 2008
  19. Vitiligo and melanoma‐associated hypopigmentation (MAH):shared and discriminative featuresJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2008
  20. Cancer treatment: the combination of vaccination with other therapiesCancer Immunology Immunotherapy · 2008
  21. Two‐year clinical results following treatment of peri‐implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membraneJournal Of Clinical Periodontology · 2007
  22. Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy ResponseClinical Cancer Research · 2007
  23. The Universal Character of the Tumor-Associated Antigen SurvivinClinical Cancer Research · 2007
  24. Profiling Chemokines, Cytokines and Growth Factors in Human Early Pregnancy Decidua By Protein ArrayAmerican Journal of Reproductive Immunology · 2007
  25. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphomaBritish Journal of Cancer · 2007
  26. Transport of Streptococcus pneumoniae Capsular Polysaccharide in MHC Class II TubulesPLoS Pathogens · 2007
  27. Imatinib in Melanoma: A Selective Treatment Option Based on KIT Mutation Status?Journal of Clinical Oncology · 2007
  28. B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact PrognosisPLoS ONE · 2007
  29. Molecularly targeted therapy for melanomaCancer · 2006
  30. Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approachesJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2006
  31. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancerJournal of Translational Medicine · 2006
  32. New insights into the molecular biology and targeted therapy of cutaneous T‐cell lymphomasJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2006
  33. Clinical and histological healing pattern of peri‐implantitis lesions following non‐surgical treatment with an Er:YAG laserLasers in Surgery and Medicine · 2006
  34. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cellsInternational Journal of Cancer · 2006
  35. HLA-B8 association with late-stage melanoma – an immunological lesson?BMC Medicine · 2006
  36. Influence of plaque biofilm removal on reestablishment of the biocompatibility of contaminated titanium surfacesJournal of Biomedical Materials Research Part A · 2006
  37. New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitorsJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2006
  38. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case reportBMC Cancer · 2006
  39. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology GroupJournal of Clinical Oncology · 2005
  40. Spontaneous Immunity against Bcl-xL in Cancer PatientsThe Journal of Immunology · 2005
  41. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptorProceedings of the National Academy of Sciences · 2005
  42. Lack of clinical efficacy of imatinib in metastatic melanomaBritish Journal of Cancer · 2005
  43. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanomaBritish Journal of Cancer · 2004
  44. Immunogenicity of Bcl-2 in patients with cancerBlood · 2004
  45. Immunogenicity of Constitutively Active V599EBRafCancer Research · 2004
  46. T-cell clonotypes in cancerJournal of Translational Medicine · 2004
  47. Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction ProfilesCancer Biology & Therapy · 2004
  48. HLA‐B35‐restricted immune responses against survivin in cancer patientsInternational Journal of Cancer · 2004
  49. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.Journal of Carcinogenesis · 2004
  50. Anorectal melanoma: surgical management guidelines according to tumour thicknessBritish Journal of Cancer · 2003